JAK-IN-21
Modify Date: 2024-01-29 19:00:46
JAK-IN-21 structure
|
Common Name | JAK-IN-21 | ||
|---|---|---|---|---|
| CAS Number | 2445499-20-5 | Molecular Weight | 372.38 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H16N8O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of JAK-IN-21JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively[1]. |
| Name | JAK-IN-21 |
|---|
| Description | JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
JAK1:1.73 nM (IC50) JAK2:2.04 nM (IC50) Tyk2:62.9 nM (IC50) JAK2-V617F:109 nM (IC50) |
| In Vitro | JAK-IN-21 (Example 4) doses not inhibit CYPs and shows good liver microsome stability[1]. |
| In Vivo | JAK-IN-21 (Example 4) shows low bioavailability (F=1.9%)[1]. Animal Model: SD rats[1] Dosage: 10 mg/kg Administration: Oral gavage (Pharmacokinetic Study) Result: Rat Colon Pharmacokinetic Study[1] Compound Plasma Cmax (ng/mL) Plasma AUC (h*ng/mL) t1/2 (h) Colon AUC (h*ng/g) Colon + Feces AUC (h*ng/g) JAK-IN-21 68.8 96 1.6 6,623 545,501 Animal Model: SD rats[1] Dosage: 1 mg/kg or 2 mg/kg Administration: Intravenous injection (1 mg/kg) or oral gavage (2 mg/kg) (Pharmacokinetic Study) Result: Pharmacokinetic Parameters in Sprague-Dawley Rats by Intravenous Administration and Oral Administration[1] Compound Dose (mg/kg) AUC (h*ng/mL) T1/2 (h) Cl (mL/min/kg) Vd (L/kg) Cmax (ng/mL) F (%) JAK-IN-21 (iv) 1 854.8 0.22 19.4 0.37 JAK-IN-21 (ig) 2 29.8 0.38 40.4 1.9 |
| References |
| Molecular Formula | C19H16N8O |
|---|---|
| Molecular Weight | 372.38 |